Peter White, Robin Lane, Helen Upton, Julie Chiu, Sue Faulconbridge
BASi®, Suite 2 Building 500, Abbey Park, Stareton, Kenilworth, Warwickshire, UK
Inhaled drugs used in the treatment of asthma and/or chronic obstructive pulmonary disease (COPD) have a low-systemic exposure. Plasma concentrations of Formoterol and Fluticasone Propionate (Figures 1 and 2) at therapeutic inhaled dose ranges are extremely low and require sensitive assays with sufficient LLOQ's to determine the relevant pharmacokinetic parameters. Two highly sensitive analytical methods have been developed for the quantitation of Formoterol Fumarate and Fluticasone Propionate in human plasma.